KeyZell continues to advance in the development of its Artificial Intelligence tool

The biotech startup KeyZell has officially announced the launch of its exclusive fungible token useful to receive the service of its Artificial Intelligence system for precision medicine against cancer, and another non-fungible token of the industrial property of this AI.

The startup has developed OPS (Oncology Precision System), an AI solution capable of proposing the best combination of personalized cancer treatments for each patient, through a Machine Learning system.

This innovative solution makes it easier for oncologists to define and select the most appropriate treatment for each patient, taking into account their individual genetic characteristics.

Given the strong economic entry barriers for new companies in the pharmaceutical sector, the issuance of K2Z is ​​a step towards advancing the project to fight cancer based on precision medicine and AI

KeyZell will hold a Token Generation Event (TGE) through the K2Z Utility Token project, based on the maximum issuance of 2 billion tokens and 20,000 NFTs.

Thus, with this TGE, it intends to demonstrate the efficacy of a new generation of first-line drugs for the treatment of cancer, as well as to obtain a more advanced version of its AI solution.

The project consists of the tokenization of the industrial property of its AI system by issuing a maximum of 2,000 million tokens and 20,000 NFTs. Users will earn one NFT for every 100,000 tokens.

The token will run natively on the Binance Smart Chain network blockchain following the BEP-20 standard. Thus, these users will benefit from the ability of this industrial property to generate new tokens and participate in an airdrop.

“The K2Z issue aims to radically change the situation in the health sector, eliminating the economic barriers to entry in the market, and being able to work on the most important purpose, saving lives, and not use it as a mere speculative investment”

“With the utility of this token, we want to bring a diagnostic service for personalized precision medicine cancer treatment and for patients to be able to obtain new tokens each year with NFTs to use them with AI”, José de Corral, CEO of KeyZell.

About KeyZell

Formed by a multidisciplinary group of professionals from various fields, researchers from recognized centers of high prestige such as the University of Seville, the University of Malaga or the Imperial College of London, engineers with management experience in large international projects and senior professionals from the sectors pharmaceutical, legal and business.

The company is also supported by a highly qualified team of advisers, not only in the medical or scientific field, but also in intellectual property, legal or strategic matters.

He is currently working on several lines of research, on the one hand, a new first-line treatment against some types of tumors, pending the start of a phase I/IIa clinical trial, a pre-clinical phase treatment to prevent metastasis.

On the other hand, it develops the innovative artificial intelligence system KEYZELL OPS, for which it already has its industrial license, and which aims to be the future of precision medicine in oncology, and which is based on the search for patterns and personalized treatments for those cancer patients who do not respond to treatment, offering the most appropriate treatment for cancer, in the appropriate order and at the most appropriate time according to the characteristics of each patient.

The startup has recently been awarded the Isaac Peral National Research, Science and Innovation Awards by the European Association for Economy and Competitiveness (AEDEEC), and has been recognized by the British magazine Health Tech World as one of the 50 best companies innovators in technology in the health sector in 2022.

It is important to read and understand the risks of this investment which are explained in detail at this location .

“Investing in crypto assets is not regulated, may not be suitable for retail investors and may lose the entire amount invested”

See here the complete article of Bitcoin Territory.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Recent news

Follow us on the networks

Subscribe to our newsletters

You will only receive notifications about new news and updates.

More news

KeyZell awarded with the Andalucía Excelente prize, best Biotechnology company 2022.

KeyZell received the Andalucía Excelente Award as the best Biotechnology company 2022. KeyZell, awarded for its commitment to create a new future for oncology, through …

Read more →

Fourier Intelligence, iRhythm and KeyZell are the most internationally recognized companies for revolutionizing the health sector

Health Tech World has released a compilation of the top 50 health technology innovators of 2022 who stand out for their unique innovation, outstanding technology …

Read more →

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe”

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe” in the seventh edition of the “International Life Sciences Awards 2022“. This event …

Read more →

Revealed: The Health Tech World Top 50 Innovators of 2022

Health Tech World has announced its Top 50 health tech innovators of 2022. Here are the top picks of health tech companies who stand out …

Read more →

The capital dresses up for science

The European Association of Economy and Competitiveness celebrates the second edition of the Isaac Peral National Award for Research, Science and Innovation The investigation was …

Read more →

Artificial intelligence: key to optimizing clinical decisions in cancer patients

“The OPS (Oncology Precision System) starts from the genetic characteristics of each patient and is capable of proposing the best combination of treatments currently available …

Read more →

KeyZell boosts its cancer treatments

Receive an award for an Artificial Intelligence development.  KeyZell promotes its cancer treatments and for this it has received an award in the II Edition …

Read more →

KeyZell Awarded for Treating Cancer with Biotechnology, Artificial Intelligence

06.28.2022 2:48 pm Biotechnological startup Keisel has been honored at the second edition of the Isaac Perel National Research, Science and Innovation Awards organized by …

Read more →

KeyZell revolutionizes the fight against lung and breast cancer with an Artificial Intelligence tool

The Spanish biotechnology startup KeyZell, in alliance with the technology company Iakan, has presented an Artificial Intelligence solution capable of recommending personalized treatments for lung …

Read more →